QIAGEN Digital Insights launches ultra-fast NGS analysis for somatic cancer
QIAGEN Digital Insights (QDI), the bioinformatics business of QIAGEN, today announced their enhanced QIAGEN CLC Genomics Workbench Premium…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
31 Jan 24
QIAGEN Digital Insights (QDI), the bioinformatics business of QIAGEN, today announced their enhanced QIAGEN CLC Genomics Workbench Premium…
31 Jan 24
This platformization of new technologies will enable our clients to accelerate the discovery of preclinical ADC candidates (PCCs)…
31 Jan 24
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment…
30 Jan 24
Gilead has also made a $320m equity investment in Arcus and appointed its chief commercial officer Johanna Mercier…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
30 Jan 24
In the trial, SRP-5051, at the higher, target dose, resulted in mean dystrophin expression of 5.17%, and mean…
30 Jan 24
The approval was based on findings from an ADVANCE-CIDP 2 study in which the response rate was observed…
30 Jan 24
The approval was based on results from the Phase 3 MOMENTUM trial in which Omjjara met all its…
30 Jan 24
Through the acquisition, Roche gains access to Carmot's comprehensive research and development (R&D) portfolio, encompassing both clinical and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
30 Jan 24
Synthekine to receive $40 million upfront payment and eligible to receive milestones, in addition to tiered royalties on…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
29 Jan 24
The FDA approval, which expands Dupixent’s initial approval granted in May 2022, for the treatment of EoE in…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates